Marzena J. Fabis‐Pedrini
YOU?
Author Swipe
View article: 3614 Preserving neurological function in people at high and low risk of aggressive multiple sclerosis
3614 Preserving neurological function in people at high and low risk of aggressive multiple sclerosis Open
View article: Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability Open
Importance Understanding the association between pregnancy and clinical outcomes in women with moderate to severe multiple sclerosis (MS) disability is crucial for guiding family planning and management strategies. Objective To assess peri…
View article: C4 genetic structural variations affect multiple sclerosis risk and progression
C4 genetic structural variations affect multiple sclerosis risk and progression Open
Objective Major histocompatibility complex (MHC) locus carries a significant genetic risk burden for multiple sclerosis (MS). Here we investigate the structurally diverse complement component 4 ( C4 ) alleles within the MHC in MS developme…
View article: Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data Open
View article: COVID-19 Vaccine Boosters in People With Multiple Sclerosis
COVID-19 Vaccine Boosters in People With Multiple Sclerosis Open
Despite not eliciting adequate antibody response in pwMS on IMM-DMT, COVID-19 boosters improve the breadth of the humoral response against SARS-CoV-2 emerging variants. Vaccine protection can be predicted by statistical modeling.
View article: Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024) Open
Background: Family planning is an important aspect of multiple sclerosis (MS), and neuromyelitis optica spectrum disorder (NMOSD) management. Knowledge gaps remain, including optimal perinatal management strategies, and fetal risks associa…
View article: Design, acceptability, and measured outcomes of music interventions for walking in persons with multiple sclerosis: A scoping review
Design, acceptability, and measured outcomes of music interventions for walking in persons with multiple sclerosis: A scoping review Open
Review findings on existing evidence of auditory-motor coupling in persons with MS indicate good user acceptability. However consideration of participants' characteristics, such as musical experience and MS symptoms, and auditory stimuli c…
View article: Correction: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications
Correction: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications Open
View article: Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies Open
This study provides Class III evidence that for women with relapsing-remitting MS or clinically isolated syndrome who become pregnant, ocrelizumab, rituximab, and natalizumab (continued ≥28 weeks of gestation and restarted ≤1 month postpar…
View article: The clinical relevance of <scp>MOG</scp> antibody testing in cerebrospinal fluid
The clinical relevance of <span>MOG</span> antibody testing in cerebrospinal fluid Open
Myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) is diagnosed by serum MOG‐immunoglobulin G (MOG‐IgG) in association with typical demyelination. 111/1127 patients with paired CSF/serum samples were seropositive for M…
View article: A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic Open
View article: The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease
The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease Open
Background Myelin oligodendrocyte glycoprotein (MOG) IgG seropositivity is a prerequisite for MOG antibody-associated disease (MOGAD) diagnosis. While a significant proportion of patients experience a relapsing disease, there is currently …
View article: Investigation of Genomic Mimicry and Multimorbidity in Multiple Sclerosis Using Exome Sequencing
Investigation of Genomic Mimicry and Multimorbidity in Multiple Sclerosis Using Exome Sequencing Open
View article: 6 Spike antibody seroconversion and emerging variant cross-reactivity following COVID-19 third vaccination dose in Australian people with multiple Sclerosis
6 Spike antibody seroconversion and emerging variant cross-reactivity following COVID-19 third vaccination dose in Australian people with multiple Sclerosis Open
Background COVID-19 vaccination-induced Spike antibodies are attenuated in people living with multiple sclerosis (pwMS) on high-efficacy disease-modifying therapies (DMTs). It is currently unknown whether vaccine boosters will elicit a gre…
View article: Locus for severity implicates CNS resilience in progression of multiple sclerosis
Locus for severity implicates CNS resilience in progression of multiple sclerosis Open
View article: Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis Open
Background: The prognostic significance of non-disabling relapses in people with relapsing-remitting multiple sclerosis (RRMS) is unclear. Objective: To determine whether early non-disabling relapses predict disability accumulation in RRMS…
View article: Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome
Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome Open
Objective To determine whether serum neurofilament light chain (sNfL) levels are suppressed in patients with the clinically isolated syndrome (CIS) following narrowband ultraviolet B phototherapy (UVB‐PT). Methods sNfL levels were measured…
View article: MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis
MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis Open
Neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) are inflammatory diseases of the CNS. Overlap in the clinical and MRI features of NMOSD and MS means that distinguishing these conditions can be difficult. With the…
View article: Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)
Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study) Open
Background Cladribine tablets (marketed as Mavenclad) are a new oral therapy, which has recently been listed on the pharmaceutical benefits scheme in Australia for the treatment of relapsing multiple sclerosis (MS). The current dosing sche…
View article: Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study) (Preprint)
Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study) (Preprint) Open
BACKGROUND Cladribine tablets (marketed as Mavenclad) are a new oral therapy, which has recently been listed on the pharmaceutical benefits scheme in Australia for the treatment of relapsing multiple sclerosis (MS). The current dosing sch…
View article: Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation
Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation Open
Neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) show overlap in their clinical features. We performed an analysis of relapses with the aim of determining differences between the two conditions. Cases of NMOSD an…
View article: 134 Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS)
134 Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS) Open
Introduction Cladribine tablets (marketed as Mavenclad®) is a new oral therapy, which has recently been listed on the pharmaceuticals benefit scheme (PBS) in Australia for treatment of relapsing MS. The current dosing schedule is for 2 cou…
View article: Short-term changes in frequencies of circulating leukocytes associated with narrowband UVB phototherapy in people with clinically isolated syndrome
Short-term changes in frequencies of circulating leukocytes associated with narrowband UVB phototherapy in people with clinically isolated syndrome Open
View article: Higher Serum Immunoglobulin G3 Levels May Predict the Development of Multiple Sclerosis in Individuals With Clinically Isolated Syndrome
Higher Serum Immunoglobulin G3 Levels May Predict the Development of Multiple Sclerosis in Individuals With Clinically Isolated Syndrome Open
Clinically isolated syndrome (CIS) is a first episode of neurological symptoms that may precede a diagnosis of multiple sclerosis (MS). Therefore, studying individuals with CIS may lead to breakthroughs in understanding the development and…
View article: A randomised, controlled clinical trial of narrowband UVB phototherapy for clinically isolated syndrome: The PhoCIS study
A randomised, controlled clinical trial of narrowband UVB phototherapy for clinically isolated syndrome: The PhoCIS study Open
Background The natural history of multiple sclerosis (MS) typically presents with the clinically isolated syndrome (CIS), an episode of neurological symptoms caused by central nervous system inflammation or demyelination that does not fulf…
View article: Tryptophan and arginine catabolic enzymes and regulatory cytokines in clinically isolated syndrome and multiple sclerosis
Tryptophan and arginine catabolic enzymes and regulatory cytokines in clinically isolated syndrome and multiple sclerosis Open
Objectives Clinically isolated syndrome ( CIS ) is the earliest clinical episode in multiple sclerosis ( MS ). A study of circulating cells from patients with CIS may help us understand the transition to, and processes associated with, the…
View article: Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis Open
Objective: This propensity score–matched analysis from MSBase compared the effectiveness of cladribine with interferon β, fingolimod or natalizumab. Methods: We identified all patients with relapse-onset multiple sclerosis, exposure to the…
View article: Evolving Identification of Blood Cells Associated with Clinically Isolated Syndrome: Importance of Time since Clinical Presentation and Diagnostic MRI
Evolving Identification of Blood Cells Associated with Clinically Isolated Syndrome: Importance of Time since Clinical Presentation and Diagnostic MRI Open
It is not clear how the profile of immune cells in peripheral blood differs between patients with clinically isolated syndrome (CIS) and healthy controls (HC). This study aimed to identify a CIS peripheral blood signature that may provide …
View article: Fabry heterozygote mimicking multiple sclerosis
Fabry heterozygote mimicking multiple sclerosis Open
Fabry’s disease (FD) is a recognised mimic of multiple sclerosis (MS). It is an X-linked storage lysosomal disorder with deficiency of α-galactosidase A and enzyme replacement therapy is available. Patients with FD may satisfy modified McD…
View article: Altered regulatory T‐cell fractions and Helios expression in clinically isolated syndrome: clues to the development of multiple sclerosis
Altered regulatory T‐cell fractions and Helios expression in clinically isolated syndrome: clues to the development of multiple sclerosis Open
Development of multiple sclerosis (MS) is frequently preceded by an acute or subacute neurological disturbance referred to as clinically isolated syndrome (CIS). The specific immunological disturbances present in CIS remain underexamined. …